NEW YORK, NY, June 30, 2026 /24-7PressRelease/ -- Ace Therapeutics, a leading preclinical contract research organization focused on analgesic drug research, announces its robust end-to-end solutions dedicated to advancing pain therapeutic development, featuring diverse validated in vivo pain models for drug testing and a complete suite of preclinical research capabilities for pharmaceutical and biotechnology customers worldwide.

Specializing in preclinical analgesic drug development services, Ace Therapeutics covers every stage from early target discovery and mechanism verification through to pharmacological validation and safety assessment, addressing the complex demands of modern pain drug research. Rooted in scientific rigor and regulatory-compliant methodologies, Ace Therapeutics builds integrated in vitro and in vivo research platforms tailored to study various physiological pain mechanisms, evaluate compound efficacy, and conduct safety profiling for novel analgesic candidates.

A core strength of Ace Therapeutics lies in its extensive portfolio of standardized and customized in vivo pain models for drug testing, which span nearly all mainstream pain classifications to meet diverse research requirements. These validated animal models include migraine models established via trigeminal ganglion electrical stimulation, nitroglycerin induction and other approaches, as well as multiple neuropathic pain models such as spinal nerve ligation, chronic constriction injury, and diabetic neuropathic pain models.

To complement its in vivo systems, Ace Therapeutics has developed systematic preclinical pain assessment services, including mechanical pain, thermal pain, chemical pain, cold pain, and electrical stimulation pain assessments using well-established testing methods like the Von Frey Filament Test, Hot Plate Test, and Formalin Test. Meanwhile, the in vitro neuropathic pain model development services leverage dorsal root ganglion (DRG) cells, iPSC-derived sensory neurons, and various co-culture systems to explore pain-related cellular mechanisms, further enhancing the translational value of preclinical research.

Beyond model construction and efficacy testing, Ace Therapeutics' preclinical analgesic drug development services extend to target-based and modality-based drug discovery. These services support research targeting G-protein coupled receptors, cytokine networks, and various ion channels (including voltage-gated channels), delivering professional solutions for small-molecule analgesics, biologics, including antibodies, recombinant proteins, peptides, cell therapies, and gene therapy candidates. It also offers mechanism-driven research covering peripheral inflammatory pathways, central regulatory pathways, neuronal signaling pathways, and neuro-immune interaction pathways.

The full-service pipeline of Ace Therapeutics also includes target validation, in vitro screening, in vivo pharmacology research, pharmacokinetics analysis, safety pharmacology, preclinical formulation development, and biomarker discovery. Professional PK/PD modeling, toxicity assessment, and formulation optimization help clients reduce research risks, determine optimal dosages, and accelerate candidate selection for analgesic drugs. For special research needs, Ace Therapeutics can also design customized pain models and testing assays according to unique drug mechanisms and research objectives.

About Ace Therapeutics
Ace Therapeutics is a professional preclinical contract research organization focusing on analgesic drug development. It provides one-stop preclinical research services covering target validation, model construction, efficacy evaluation, mechanism research, and safety assessment. Equipped with extensive experience in pain research and a full range of in vitro and in vivo research platforms, Ace Therapeutics is committed to helping global pharmaceutical and biotech companies advance the research and development of novel analgesic drugs.

This contant was orignally distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Ace Therapeutics Announces Comprehensive Preclinical Analgesic Drug Development Services with Full-Spectrum Pain Research Platform.